ClinicalTrials.gg
RecruitingNCT06548360TRuE-VIP1Updated Sep 14, 2026

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

A Phase 3 interventional study of Ruxolitinib Cream and Vehicle Cream in NonSegmental Vitiligo, sponsored by Incyte Corporation. Recruiting at 98 sites in 2 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
2 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing ruxolitinib in Vitiligo — 5 open to participants now, 5 under way, 4 of them phase 3. ruxolitinib · Vitiligo.

Planned enrollment
5th of 14
180 · median 90
Started
2025
with 2 others
Phase 3
6 of 14
3 open now
Registered
9th of 14
by date
Lead sponsor
9 of 14
Incyte Corporation

Among the 14 studies testing ruxolitinib in Vitiligo, this one is the 5th largest by planned enrollment, is one of 3 that started in 2025, is one of 6 in phase 3, and was the 9th registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

5 of the 14 studies testing ruxolitinib in Vitiligo are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 2 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing ruxolitinib in Vitiligo, or all of them as a file.
02

Study summary

The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.

03

Conditions studied

  • NonSegmental Vitiligo

Browse trials for

Keywords

  • NonSegmental Vitiligo
  • pediatric
04

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of nonsegmental vitiligo with depigmented area including ≥ 0.5% BSA on the face, ≥ 0.5 F-VASI, ≥ 2% BSA on nonfacial areas, ≥ 2 T-VASI.
  • Total body vitiligo area does not exceed 10% BSA.
  • Pigmented hair within some of the areas of vitiligo on the face.
  • Must agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit.
  • For sexually active participants (except participants who are prepubescent) willingness to avoid pregnancy or fathering a child from screening through 30 days after the last application of study cream.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of other forms of vitiligo (eg, segmental).
  • Other differential diagnosis of vitiligo or other skin depigmentation disorders (eg, piebaldism, pityriasis alba, leprosy, postinflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus, chemical leukoderma, and tinea versicolor).
  • Any other skin disease that, in the opinion of the investigator, would interfere with the study drug application or study assessments.
  • Prior or current use of depigmentation treatments (eg, monobenzone).
  • Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full participation in the study, including application of study cream and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
  • Use of protocol-defined treatments within the indicated before baseline.
  • History of treatment failure with any systemic or topical JAK inhibitor (eg, ruxolitinib, tofacitinib, baricitinib, abrocitinib, and upadacitinib) for vitiligo or any other inflammatory condition.
  • Protocol-defined abnormal laboratory values at screening.
  • Pregnant or lactating participants or those considering pregnancy during the period of their study participation.
  • In the opinion of the investigator, unable or unlikely to comply with the application schedule and study evaluations.
  • Living with anyone participating in any current Incyte-sponsored ruxolitinib cream study.
  • Employees of the sponsor or investigator or are otherwise dependents of them.
  • Known allergy or reaction to any component of the study cream formulation.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Ruxolitinib 1.5 % Cream

    Participants received ruxolitinib 1.5% cream, applied topically to the affected area as defined in the protocol.

    Drug: Ruxolitinib Cream

  • Placebo comparator
    Vehicle Cream

    Participants received vehicle cream, applied topically to the affected area as defined by the protocol.

    Drug: Vehicle Cream

Interventions

  • Ruxolitinib cream applied topically to the affected area as a thin film twice daily.

    Also known as: INCB018424 Phosphate Cream

  • DrugVehicle Cream

    Matching vehicle cream applied topically to the affected area as a thin film twice daily.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75)

    ≥75% improvement in facial Vitiligo Area Scoring Index.

    Time frame: Week 24

Secondary outcomes

  1. Proportion of Participants Achieving Facial Vitiligo Area Scoring Index (F-VASI50)

    ≥50% improvement in facial Vitiligo Area Scoring Index.

    Time frame: Week 24

  2. Proportion of Participants Achieving Facial Vitiligo Area Scoring Index (F-VASI90)

    ≥90% improvement in facial Vitiligo Area Scoring Index.

    Time frame: Week 24

  3. Proportion of Participants Achieving a ≥ 50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50)

    ≥50% improvement in total body Vitiligo Area Scoring Index.

    Time frame: Week 24

  4. Percentage change from baseline in F-BSA

    Facial body surface area (F-BSA) takes into account the facial depigmented areas as a percentage of the total body area.

    Time frame: Week 24

  5. Number of Treatment Emergent Adverse Events (TEAEs)

    TEAE defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.

    Time frame: Up to Week 52 and 30 days

  6. Proportion of Participants Achieving Facial Vitiligo Area Scoring Index (F-VASI50)

    ≥50% improvement in facial Vitiligo Area Scoring Index.

    Time frame: Week 52

  7. Proportion of Participants Achieving Facial Vitiligo Area Scoring Index (F-VASI75)

    ≥75% improvement in facial Vitiligo Area Scoring Index.

    Time frame: Week 52

  8. Proportion of Participants Achieving Facial Vitiligo Area Scoring Index (F-VASI90)

    ≥90% improvement in facial Vitiligo Area Scoring Index.

    Time frame: Week 52

  9. Proportion of Participants Achieving Total Body Vitiligo Area Scoring Index (T-VASI50)

    ≥50% improvement in total body Vitiligo Area Scoring Index.

    Time frame: Week 52

  10. Proportion of Participants Achieving Total Body Vitiligo Area Scoring Index (T-VASI25)

    ≥25% improvement in total body Vitiligo Area Scoring Index.

    Time frame: Week 24 and Week 52

  11. Proportion of Participants Achieving Total Body Vitiligo Area Scoring Index (T-VASI75)

    ≥75% improvement in total body Vitiligo Area Scoring Index

    Time frame: Week 24 and Week 52

  12. Proportion of Participants Achieving Total Body Vitiligo Area Scoring Index (T-VASI90)

    ≥90% improvement in total body Vitiligo Area Scoring Index

    Time frame: Week 24 and Week 52

  13. Pharmacokinetic (PK) of Ruxolitinib: Trough concentrations

    Trough is defined as the concentration reached by a drug immediately before the next dose is administered.

    Time frame: Weeks 6, 24, 30 and 52

07

Study locations

83 of 98 sites recruiting
  • University of Alabama At Birmingham-School of Medicine
    Birmingham, Alabama 35233, United States
    Recruiting
  • Saguaro Dermatology
    Phoenix, Arizona 85008, United States
    Recruiting
  • Phoenix Children'S Hospital
    Phoenix, Arizona 85016, United States
    Recruiting
  • Omni Dermatology
    Phoenix, Arizona 85037, United States
    Recruiting
  • Affiliated Dermatology
    Scottsdale, Arizona 85255, United States
    Completed

    Not enrolling at this site — choose another above.

  • Banner - University Medicine Multispecialty Services Clinic
    Tucson, Arizona 85718, United States
    Recruiting
  • Premier Dermatology Clinical Trials Institute At Northwest Arkansas
    Fayetteville, Arkansas 72703, United States
    Recruiting
  • Burke Pharmaceutical Research
    Hot Springs, Arkansas 71913, United States
    Completed

    Not enrolling at this site — choose another above.

  • Axon Clinical Research
    Inglewood, California 90301, United States
    Recruiting
  • University of California Irvine
    Irvine, California 92697, United States
    Recruiting
  • Vitiligo & Pigmentation Institute of Southern California
    Los Angeles, California 90036-5609, United States
    Recruiting
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
    Recruiting
  • La Universal Research Center, Inc
    Los Angeles, California 90057, United States
    Recruiting
  • Stanford School of Medicine
    Palo Alto, California 94304, United States
    Recruiting
  • Empire Clinical Research
    Pomona, California 91767, United States
    Recruiting
  • Peninsula Research Associates Pra
    Rolling Hills Estates, California 90274-7604, United States
    Completed

    Not enrolling at this site — choose another above.

  • Rady Children'S Hospital-San Diego
    San Diego, California 92123, United States
    Recruiting
  • Golden State Dermatology
    Walnut Creek, California 94598, United States
    Not yet recruiting
  • Children'S Hospital Colorado
    Aurora, Colorado 80045, United States
    Recruiting
  • Paradigm Clinical Research Centers, Inc.
    Wheat Ridge, Colorado 80033, United States
    Recruiting
  • Skin Care Research, Llc
    Boca Raton, Florida 33486, United States
    Recruiting
  • Encore Medical Research, Llc Boynton Beach
    Boynton Beach, Florida 33436, United States
    Recruiting
  • Skin Care Research, Llc
    Hollywood, Florida 33201, United States
    Recruiting
  • Solutions Through Advanced Research, Inc
    Jacksonville, Florida 32256, United States
    Recruiting
  • Pediatric Skin Research Llc
    Miami, Florida 33146, United States
    Recruiting
  • Nicklaus Children'S Hospital
    Miami, Florida 33155, United States
    Recruiting
  • Dh Tamarac Research Center Etna Medical Center Emc
    Tamarac, Florida 33321, United States
    Recruiting
  • Usf Health Morsani Center For Advanced Healthcare
    Tampa, Florida 33612, United States
    Recruiting
  • Cleaver Medical Group
    Cumming, Georgia 30040, United States
    Recruiting
  • Advanced Medical Research Pc
    Sandy Springs, Georgia 30328, United States
    Recruiting
  • Treasure Valley Medical Research
    Boise, Idaho 83706, United States
    Recruiting
  • Illinois Dermatology Institute the Chicago Loop
    Chicago, Illinois 60602, United States
    Recruiting
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
    Recruiting
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
    Recruiting
  • Forefront Dermatology
    Libertyville, Illinois 60048, United States
    Not yet recruiting
  • Northshore University Healthsystem
    Skokie, Illinois 60077, United States
    Recruiting
  • Indiana University School of Medicine
    Indianapolis, Indiana 46202, United States
    Recruiting
  • Skin and Hair Center
    Overland Park, Kansas 66213, United States
    Recruiting
  • Wellskin Dermatology & Aesthetics
    Bowling Green, Kentucky 42104, United States
    Completed

    Not enrolling at this site — choose another above.

  • Tulane University Health Sciences Center
    New Orleans, Louisiana 70112, United States
    Recruiting
  • Dermatology Associates Pc
    Rockville, Maryland 20850, United States
    Recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
  • Metro Boston Clinical Partners
    Brighton, Massachusetts 02135-3511, United States
    Completed

    Not enrolling at this site — choose another above.

  • Dermatology and Cosmetic Center
    Flint, Michigan 48507, United States
    Recruiting
  • Mi Skin Center, Pllc
    Northville, Michigan 48167, United States
    Recruiting
  • Michigan Dermatology Institute
    Waterford, Michigan 48328, United States
    Recruiting
  • University of Missouri Kansas City
    Kansas City, Missouri 64108, United States
    Not yet recruiting
  • Medisearch Clinical Trials
    Saint Joseph, Missouri 64506, United States
    Completed

    Not enrolling at this site — choose another above.

  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
  • Boeson Research
    Missoula, Montana 59804, United States
    Recruiting
  • Skin Specialists Pc the Advanced Skin Research Center
    Omaha, Nebraska 68144, United States
    Recruiting
  • The University of New Mexico Unm Health Sciences Center Hsc
    Albuquerque, New Mexico 87102, United States
    Recruiting
  • Suny Downstate Medical Center
    Brooklyn, New York 11203, United States
    Recruiting
  • The Dermatology Specialists Greenwich
    New York, New York 10012, United States
    Recruiting
  • Equity Medical, Llc
    New York, New York 10023, United States
    Completed

    Not enrolling at this site — choose another above.

  • Mount Sinai Doctors
    New York, New York 10028-3135, United States
    Recruiting
  • Sadick Dermatology Sadick Research Group
    New York, New York 10075, United States
    Completed

    Not enrolling at this site — choose another above.

  • Skin Search of Rochester
    Rochester, New York 14623, United States
    Recruiting
  • Vitality Clinical Research Llc
    Woodbury, New York 11797, United States
    Recruiting
  • Red River Research Partners
    Fargo, North Dakota 58103, United States
    Recruiting
  • Wright State Physicians Health Center
    Beavercreek, Ohio 45324, United States
    Recruiting
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
    Recruiting
  • Columbia Dermatology
    Columbia, South Carolina 29212, United States
    Recruiting
  • International Clinical Research Tennessee Llc
    Murfreesboro, Tennessee 37130, United States
    Completed

    Not enrolling at this site — choose another above.

  • Dell Children'S Medical Group
    Austin, Texas 78723, United States
    Recruiting
  • The University of Texas Health Science Center At Houston
    Bellaire, Texas 77401, United States
    Recruiting
  • 3A Research Llc West Location
    El Paso, Texas 79902, United States
    Recruiting
  • Reveal Research Institute
    Frisco, Texas 75033, United States
    Recruiting
  • Acrc Trials
    Grapevine, Texas 07605, United States
    Recruiting
  • Us Dermatology Partners Longview
    Longview, Texas 75601, United States
    Completed

    Not enrolling at this site — choose another above.

  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
    Recruiting
  • Stryde Research
    Southlake, Texas 76092, United States
    Recruiting
  • University of Utah Midvalley Dermatology
    Murray, Utah 84107, United States
    Recruiting
  • Jordan Valley Dermatology Center
    South Jordan, Utah 84095, United States
    Recruiting
  • Frontier Dermatology
    Mill Creek, Washington 98012, United States
    Recruiting
  • Seattle Children'S Hospital
    Seattle, Washington 98105, United States
    Recruiting
  • Dermatology Specialists of Spokane
    Spokane, Washington 99202, United States
    Recruiting
  • University of Wisconsin School of Medicine
    Madison, Wisconsin 53715, United States
    Recruiting
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
  • Kirk Barber Research
    Calgary, Alberta T2G 1B1, Canada
    Recruiting
  • Dermatology Research Institute
    Calgary, Alberta T2J 7E1, Canada
    Recruiting
  • Alberta Health Services (Ahs) - Alberta Children'S Hospital (Ach)
    Calgary, Alberta T3B 6A8, Canada
    Recruiting
  • Laser Rejuvenation Clinics Edmonton D.T. Inc
    Edmonton, Alberta T5J 3S9, Canada
    Recruiting
  • Alberta Dermasurgery Centre
    Edmonton, Alberta T6G 1C3, Canada
    Recruiting
  • Skin Physicians
    Edmonton, Alberta T6W 4V4, Canada
    Not yet recruiting
  • Coal Harbour Rejuvenation Dermatology, Inc.
    Vancouver, British Columbia V6C 0C3, Canada
    Recruiting
  • Winnipeg Clinic
    Winnipeg, Manitoba R3C 1T6, Canada
    Recruiting
  • Maritime Dermatology
    Halifax, Nova Scotia B3K5R3, Canada
    Recruiting
  • Dermcare Clinic
    Mississauga, Ontario L4W 0C2, Canada
    Not yet recruiting
  • Dar Clinical Research Inc
    Ottawa, Ontario K2T 0N7, Canada
    Recruiting
  • University of Toronto - the Hospital For Sick Children (Sickkids)
    Toronto, Ontario M5G1X8, Canada
    Recruiting
  • Cosmetic Dermatology on Bloor
    Toronto, Ontario M5S 3B4, Canada
    Recruiting
  • Centre de Recherche St-Louis
    Montreal, Quebec H1Y 3L1, Canada
    Recruiting
  • Universite de Montreal - Centre Hospitalier Universitaire (Chu) Sainte-Justine - Centre de Recherche
    Montreal, Quebec H3T 1C5, Canada
    Recruiting
  • Centre Hospitalier Universitaire de Quebec - Centre Hospitalier de L'Universite Laval (Chul)
    Québec, Quebec G1V 4G2, Canada
    Recruiting
  • Centre de Recherche Saint-Louis
    Québec, Quebec G1W 4R4, Canada
    Recruiting
  • Saskatoon Dermatology Centre
    Saskatoon, Saskatchewan S7T 0G3, Canada
    Recruiting
  • Skincare Studio Dermatology Centre
    St. John's, A1E 1V4, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jun 2028, 40 months after the start.

Of 18 phase 3 interventional studies under Vitiligo, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 44. This study's planned 40 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2024
First posted
Aug 12, 2024
StartActual
Jan 24, 2025
Primary completionEst.
Jun 5, 2028
CompletionEst.
Dec 20, 2028
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06548360
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Aug 12, 2024
Start date
Jan 24, 2025
Primary completion
Jun 5, 2028 (estimated)
Completion
Dec 20, 2028 (estimated)
Last update
Sep 14, 2026

Study contacts

Incyte Corporation Call Center (US)
Contact
medinfo@incyte.com
1.855.463.3463
Incyte Corporation Call Center (ex-US)
Contact
eumedinfo@incyte.com
+800 00027423
Incyte Medical Monitor
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion